1568-01-0

Basic information

• Product Name: 1-Propanone, 1-(3,4-dimethoxyphenyl)-3-(dimethylamino)-
• CAS NO: 1568-01-0
• Molecular Formula: C13H19NO3
• Molecular Weight: 237.299
• Mol File: 1568-01-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Propanone, 1-(3,4-dimethoxyphenyl)-3-(dimethylamino)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Propanone, 1-(3,4-dimethoxyphenyl)-3-(dimethylamino)-(1568-01-0)
• EPA Substance Registry System: 1-Propanone, 1-(3,4-dimethoxyphenyl)-3-(dimethylamino)-(1568-01-0)

Safety Data

• Hazardous Substances Data: 1568-01-0(Hazardous Substances Data)

Usage

Structure

Structurally similar to the drug ketamine

Psychoactive substance

Known for its hallucinogenic and dissociative effects when ingested

Mechanism of action

Binds to the NMDA receptor in the brain, leading to altered perception and consciousness

Legal status

Considered a controlled substance in many countries due to its potential for abuse and addiction

Therapeutic potential

Research has shown potential for treating conditions such as depression, anxiety, and PTSD

Availability

Use is highly regulated and illegal in many places

Upstream product

• 50-00-0 formaldehyd 
• 124-40-3 dimethyl amine 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 506-59-2 N,N-dimethylammonium chloride 
• 1826-67-1 vinyl magnesium bromide 
• 155586-38-2 N,3,4-trimethoxy-N-methylbenzamide 

Downstream Products

• 1567-99-3 3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole 
• 926931-27-3 1-[3-(3,4-dimethoxyphenyl)-4,5-dihydro-pyrazol-1-yl]-2-phenyl-ethanone 
• 105906-60-3 1-(3,4-dimethoxy-phenyl)-propan-1-one semicarbazone 
• 67756-25-6 1-(3,4-dimethoxyphenyl)-4-phenylbutane-1,4-dione 
• 1835-04-7 ethyl 3,4-dimethoxyphenyl ketone 

Relevant articles and documents

ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT

Aralkyl diamine derivative of the following formula, pharmaceutically acceptable salts or uses thereof as antidepressants. The derivatives have triplex inhibiting activities of the reuptake of 5-HT, dopamine and noradrenalin, which can be administered to the patients in need of such treatment in the form of compositions orally or injectedly et al.

Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

A series of 3-aryl-3-azolylpropan-1-amines was prepared and screened for its capability of inhibiting monoamine reuptake. Analogs with nanomolar potency, good human in vitro microsomal stability, and low drug-drug interaction potential were described. In